Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Mitsutaka Kitano"'
Autor:
Keita Fukao, Yoshinori Ando, Takeshi Noshi, Mitsutaka Kitano, Takahiro Noda, Makoto Kawai, Ryu Yoshida, Akihiko Sato, Takao Shishido, Akira Naito
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0217307 (2019)
Baloxavir marboxil (BXM) is an orally available small molecule inhibitor of cap-dependent endonuclease (CEN), an essential enzyme in the initiation of mRNA synthesis of influenza viruses. In the present study, we evaluated the efficacy of BXM against
Externí odkaz:
https://doaj.org/article/8b11bc6137a14a9da7d69f51f9499fe9
Autor:
Yasushi Itoh, Reiko Yoshida, Shintaro Shichinohe, Megumi Higuchi, Hirohito Ishigaki, Misako Nakayama, Van Loi Pham, Hideaki Ishida, Mitsutaka Kitano, Masahiko Arikata, Naoko Kitagawa, Yachiyo Mitsuishi, Kazumasa Ogasawara, Hideaki Tsuchiya, Takahiro Hiono, Masatoshi Okamatsu, Yoshihiro Sakoda, Hiroshi Kida, Mutsumi Ito, Le Quynh Mai, Yoshihiro Kawaoka, Hiroko Miyamoto, Mari Ishijima, Manabu Igarashi, Yasuhiko Suzuki, Ayato Takada
Publikováno v:
PLoS Pathogens, Vol 10, Iss 6, p e1004192 (2014)
Highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype often cause severe pneumonia and multiple organ failure in humans, with reported case fatality rates of more than 60%. To develop a clinical antibody therapy, we generated a human-m
Externí odkaz:
https://doaj.org/article/85e68b6456eb4b0ebb63a532351603e3
Autor:
Van Loi Pham, Misako Nakayama, Yasushi Itoh, Hirohito Ishigaki, Mitsutaka Kitano, Masahiko Arikata, Hideaki Ishida, Naoko Kitagawa, Shintaro Shichinohe, Masatoshi Okamatsu, Yoshihiro Sakoda, Hideaki Tsuchiya, Shinichiro Nakamura, Hiroshi Kida, Kazumasa Ogasawara
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e75910 (2013)
Pandemic (H1N1) 2009 influenza virus spread throughout the world since most people did not have immunity against the virus. In the post pandemic phase when many humans might possess immunity against the pandemic virus, one of the concerns is infectio
Externí odkaz:
https://doaj.org/article/fe7c12e73f794def8635ea8987099fdb
Autor:
Misako Nakayama, Shintaro Shichinohe, Yasushi Itoh, Hirohito Ishigaki, Mitsutaka Kitano, Masahiko Arikata, Van Loi Pham, Hideaki Ishida, Naoko Kitagawa, Masatoshi Okamatsu, Yoshihiro Sakoda, Takaya Ichikawa, Hideaki Tsuchiya, Shinichiro Nakamura, Quynh Mai Le, Mutsumi Ito, Yoshihiro Kawaoka, Hiroshi Kida, Kazumasa Ogasawara
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82740 (2013)
H5N1 highly pathogenic avian influenza virus (HPAIV) infection has been reported in poultry and humans with expanding clade designations. Therefore, a vaccine that induces immunity against a broad spectrum of H5N1 viruses is preferable for pandemic p
Externí odkaz:
https://doaj.org/article/80f59a51de114539adb638a3ce35ca72
Autor:
Takeshi Noshi, Akira Naito, Makoto Kawai, Ryu Yoshida, Kenji Sato, Yoshinori Ando, Ryoko Oka, Takahiro Hasegawa, Toru Ishibashi, Motoyasu Onishi, Yuki Yoshida, Takao Shishido, Mitsutaka Kitano, Akihiko Sato
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background Baloxavir acid, the active form of the orally available prodrug baloxavir marboxil, is a novel cap-dependent endonuclease inhibitor of influenza virus. Baloxavir marboxil has been shown to rapidly reduce virus titres compared with oseltami
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Scientific Reports
Scientific Reports
Neuraminidase inhibitors (NAIs) complement influenza virus infection management by helping to clear virus, alleviate symptoms, and reduce transmission. In a previous randomised study, we examined the effect of 4 NAIs on virus clearance and influenza
Autor:
Takao Shishido, Yoshinori Ando, Atsuko Yamamoto, Kazumi Matsumoto, Akira Naito, Mitsutaka Kitano, Naoko Higuchi, Takeshi Noshi, Kaoru Baba, Minoru Ikeda, Takahiro Noda, Keita Fukao
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives Baloxavir marboxil (formerly S-033188) is a first-in-class, orally available, cap-dependent endonuclease inhibitor licensed in Japan and the USA for the treatment of influenza virus infection. We evaluated the efficacy of delayed oral trea
Autor:
Takanobu Matsuzaki, Ryu Yoshida, Kenji Sato, Hiroshi Kamimori, Kaoru Baba, Akihiko Sato, Kohei Kiyota, Ryoko Oka, Akira Naito, Takao Shishido, Takahiro Noda, Mitsutaka Kitano, Yuki Yoshida, Tohru Mizutare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b38b46ac7618eec423f78d28682a36c5
https://doi.org/10.1111/irv.12760/v3/response1
https://doi.org/10.1111/irv.12760/v3/response1
Autor:
Masatoshi Okamatsu, Keiichi Taniguchi, Masanori Kobayashi, Kayo Ishida, Takao Shishido, Keiko Baba, Yoshihiro Sakoda, Yukihiro Kushima, Tomokazu Yoshinaga, Mitsutaka Kitano, Akihiko Sato, Atsuko Yamamoto, Takeshi Noshi, Makoto Kawai, Hiroshi Kida, Kazunari Hattori, Akira Naito, Shinya Omoto, Ryu Yoshida, Takashi Hashimoto
Publikováno v:
Antiviral research. 160
Cap-dependent endonuclease (CEN) resides in the PA subunit of the influenza virus and mediates the critical "cap-snatching" step of viral RNA transcription, which is considered to be a promising anti-influenza target. Here, we describe in vitro chara
Autor:
Masafumi Seki, Hiroshi Kakeya, Shigeru Kohno, Yoshifumi Imamura, Katsunori Yanagihara, Taiga Miyazaki, Mitsutaka Kitano, Shigeki Nakamura, Akitaka Tanaka, Toshiki Kajihara, Shintaro Kurihara, Naoki Iwanaga, Koichi Izumikawa, Tomoyuki Homma
Publikováno v:
Antiviral Therapy. 20:11-19
Background Pneumococcal pneumonia often occurs secondary to influenza infection and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. Peramivir is a novel, intravenous neuraminid